[Efficacy and safety of @entity11544 (exelon) in the @entity911 in the acute phase of XXXX ].

@entity1 @entity64 @entity1334 @entity911 @entity11544 @entity1767 @entity933 @entity385
There is ample evidence that the poststroke @entity911 or @entity933 is a manifestation of cholinergic deficit. Given this conception, we conducted a controlled study of efficacy and safety of acetylcholinesterase inhibitor @entity11544 in @entity1 developed a @entity933 in the acute phase of @entity385 . The study included 224 consecutive @entity64 @entity1 : 68 @entity1 developed a @entity933 in the acute phase of disease. Severity of @entity933 was scored with the Delirium Rating Scale (DRS). A main group included 21 @entity1 with @entity933 treated with @entity11544 in individually tailored doses. A control group included 47 @entity1 with @entity933 who received only vascular and anticoagulant treatment, i.e. @entity1767 . Cognitive functions were tested 3 and 6 months after @entity64 with the MMSE, the @entity1334 , the Luria 10 point verbal test. The Zarit Burden Interview (ZBI) was used after 3 and 6 months to measure caregiver burden. In @entity1 treated with @entity11544 , the @entity933 phase was significantly shorter (p<0,001) compared to the control group. In @entity1 without @entity933 in the acute phase of @entity64 , the results of neuropsychological study were better (p<0,001) than in @entity1 with @entity933 . Total ZBI scores were more favorable in the @entity11544 group than in the control one (p<0,05). To the end of the study, 5 @entity1 died in the @entity11544 group, 17 @entity1 in the control group and 3 @entity1 in the group without @entity933 . @entity11544 was safe in the acute phase of @entity64 @entity1 even after the rapid titration.
